Literature DB >> 24409064

Transforming growth factor-β and toll-like receptor-4 polymorphisms are not associated with fibrosis in haemochromatosis.

Marnie J Wood1, Lawrie W Powell1, Jeannette L Dixon1, V Nathan Subramaniam1, Grant A Ramm1.   

Abstract

AIM: To investigate the role of genetic polymorphisms in the progression of hepatic fibrosis in hereditary haemochromatosis.
METHODS: A cohort of 245 well-characterised C282Y homozygous patients with haemochromatosis was studied, with all subjects having liver biopsy data and DNA available for testing. This study assessed the association of eight single nucleotide polymorphisms (SNPs) in a total of six genes including toll-like receptor 4 (TLR4), transforming growth factor-beta (TGF-β), oxoguanine DNA glycosylase, monocyte chemoattractant protein 1, chemokine C-C motif receptor 2 and interleukin-10 with liver disease severity. Genotyping was performed using high resolution melt analysis and sequencing. The results were analysed in relation to the stage of hepatic fibrosis in multivariate analysis incorporating other cofactors including alcohol consumption and hepatic iron concentration.
RESULTS: There were significant associations between the cofactors of male gender (P = 0.0001), increasing age (P = 0.006), alcohol consumption (P = 0.0001), steatosis (P = 0.03), hepatic iron concentration (P < 0.0001) and the presence of hepatic fibrosis. Of the candidate gene polymorphisms studied, none showed a significant association with hepatic fibrosis in univariate or multivariate analysis incorporating cofactors. We also specifically studied patients with hepatic iron loading above threshold levels for cirrhosis and compared the genetic polymorphisms between those with no fibrosis vs cirrhosis however there was no significant effect from any of the candidate genes studied. Importantly, in this large, well characterised cohort of patients there was no association between SNPs for TGF-β or TLR4 and the presence of fibrosis, cirrhosis or increasing fibrosis stage in multivariate analysis.
CONCLUSION: In our large, well characterised group of haemochromatosis subjects we did not demonstrate any relationship between candidate gene polymorphisms and hepatic fibrosis or cirrhosis.

Entities:  

Keywords:  8-oxoguanine DNA glycosylase; Chemokine (C-C motif) ligand 2; Genetic polymorphism; Haemochromatosis; Interleukin 10; Liver fibrosis; Monocyte chemoattractant protein 1; Toll-like receptor 4; Transforming growth factor beta

Mesh:

Substances:

Year:  2013        PMID: 24409064      PMCID: PMC3882410          DOI: 10.3748/wjg.v19.i48.9366

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  63 in total

1.  Monocyte chemotactic protein-1 as a chemoattractant for human hepatic stellate cells.

Authors:  F Marra; R G Romanelli; C Giannini; P Failli; S Pastacaldi; M C Arrighi; M Pinzani; G Laffi; P Montalto; P Gentilini
Journal:  Hepatology       Date:  1999-01       Impact factor: 17.425

2.  Anti-chemokine therapy for the treatment of hepatic fibrosis: an attractive approach.

Authors:  Grant A Ramm
Journal:  Hepatology       Date:  2011-07       Impact factor: 17.425

3.  Is there a threshold of hepatic iron concentration that leads to cirrhosis in C282Y hemochromatosis?

Authors:  P C Adams
Journal:  Am J Gastroenterol       Date:  2001-02       Impact factor: 10.864

4.  Interleukin-10 - 1082 GG polymorphism influences the occurrence and the clinical characteristics of hepatitis C virus infection.

Authors:  Marcello Persico; Mario Capasso; Eliana Persico; Mario Masarone; Amalia de Renzo; Daniela Spano; Savino Bruno; Achille Iolascon
Journal:  J Hepatol       Date:  2006-09-22       Impact factor: 25.083

5.  Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa.

Authors:  C J Edwards-Smith; J R Jonsson; D M Purdie; A Bansal; C Shorthouse; E E Powell
Journal:  Hepatology       Date:  1999-08       Impact factor: 17.425

6.  Val64Ile polymorphism in the C-C chemokine receptor 2 is associated with reduced coronary artery calcification.

Authors:  Ana M Valdes; Megan L Wolfe; Eamonn J O'Brien; Nigel K Spurr; Warren Gefter; Andrew Rut; Pieter H E Groot; Daniel J Rader
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-11-01       Impact factor: 8.311

Review 7.  Interleukin-10 and chronic liver disease.

Authors:  Li-Juan Zhang; Xiao-Zhong Wang
Journal:  World J Gastroenterol       Date:  2006-03-21       Impact factor: 5.742

8.  TLR4 enhances TGF-beta signaling and hepatic fibrosis.

Authors:  Ekihiro Seki; Samuele De Minicis; Christoph H Osterreicher; Johannes Kluwe; Yosuke Osawa; David A Brenner; Robert F Schwabe
Journal:  Nat Med       Date:  2007-10-21       Impact factor: 53.440

9.  Interleukin 10 secretion in relation to human IL-10 locus haplotypes.

Authors:  J Eskdale; G Gallagher; C L Verweij; V Keijsers; R G Westendorp; T W Huizinga
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

Review 10.  Functional consequences of toll-like receptor 4 polymorphisms.

Authors:  Bart Ferwerda; Matthew Bb McCall; Karlijn Verheijen; Bart-Jan Kullberg; André Jam van der Ven; Jos Wm Van der Meer; Mihai G Netea
Journal:  Mol Med       Date:  2008 May-Jun       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.